Franklin Lakes, New Jersey-based BD (Becton, Dickinson and Company) (NYSE:BDX) reported financial results for the first quarter of fiscal 2026 ended December 31, 2025.
Revenue totaled $5.25 billion, increasing 1.6% as reported and 0.4% on a foreign currency-neutral (FXN) basis compared with the prior-year period.
Reported diluted earnings per share rose 28.8% to $1.34, while adjusted diluted EPS was $2.91, down 15.2% year-over-year.
The company continues to expect the previously announced combination of its Biosciences and Diagnostic Solutions businesses with Waters Corporation to close on February 9, 2026.
BD reaffirmed its full-year fiscal 2026 guidance for New BD (post-combination), expecting low single-digit revenue growth and adjusted diluted EPS in the range of $12.35 to $12.65.